Clinical Study of Jaktinib in the Treatment of Patients With Moderate and Severe Atopic Dermatitis

• Status: Recruiting
• Trial end date: 2022-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the efficacy and safety of Jaktinib in participants with moderate to severe atopic dermatitis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Criteria

Inclusion Criteria:

• Meet the Chinese diagnostic criteria for atopic dermatitis (Zhang's criteria) and be diagnosed as atopic dermatitis.

• Participants must have moderate to severe AD at screening and randomization.

• Participants must have inadequate response to topical medications within 6 months of screening.

• Agree to use emollients daily

Exclusion Criteria:

• Received prior treatment with any oral Janus kinase (JAK) inhibitor less than 4 weeks prior to randomization.

• Have received certain types of vaccinations.

• Participants who do not agree to use adequate contraception during the trial and within 4 weeks after the last dose.

• Any Participants whom the investigator deems inappropriate for participation in this clinical study